3,77 €
1,00 % heute
L&S, 29. Oktober, 08:43 Uhr
ISIN
US5171251003
Symbol
LRMR
Berichte

Larimar Therapeutics Inc Aktie News

Neutral
PRNewsWire
13 Tage alt
LOS ANGELES , Oct. 16, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company") (NASDAQ: LRMR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to inves...
Neutral
Business Wire
13 Tage alt
LOS ANGELES--(BUSINESS WIRE)--Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR.
Neutral
Seeking Alpha
30 Tage alt
Larimar Therapeutics, Inc. - Special Call Company Participants Carole Ben-Maimon - CEO, President & Director Conference Call Participants Alexandra Folias Yatin Suneja - Guggenheim Securities, LLC, Research Division Joori Park - Leerink Partners LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Myles Minter - Willi...
Neutral
GlobeNewsWire
30 Tage alt
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered by a ca...
Neutral
GlobeNewsWire
etwa ein Monat alt
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT
Neutral
GlobeNewsWire
3 Monate alt
* Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65.1 million in net proceeds from the recently completed July 2025 public offering.
Neutral
GlobeNewsWire
3 Monate alt
BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters' option ...
Neutral
GlobeNewsWire
3 Monate alt
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross ...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen